Ashfords advised life sciences company Iksuda Therapeutics on the deal. Bird & Bird advised Mirae Asset Capital, Celltrion and Premier Partners. Iksuda is the developer of...
Iksuda Therapeutics’ £29.6 Million Series A Financing Round
Iksuda Therapeutics’ £29.6 Million Series A Financing Round
Ashfords advised life sciences company Iksuda Therapeutics on the deal. Bird & Bird advised Mirae Asset Capital, Celltrion and Premier Partners. Iksuda is the developer of...